178
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis

ORCID Icon, , ORCID Icon, & ORCID Icon
Pages 21-28 | Published online: 20 Feb 2020

References

  • Acthar® Gel (repository corticotropin injection) [prescribing information]; 2019 Available From: https://www.acthar.com/pdf/Acthar-PI.pdf. Accessed 58, 2019.
  • Ross AP, Ben-Zacharia A, Harris C, Smrtka J. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol. 2013;4:21. doi:10.3389/fneur.2013.0002123482896
  • Montero-Melendez T. ACTH: the forgotten therapy. Semin Immunol. 2015;27:216–226. doi:10.1016/j.smim.2015.02.00325726511
  • Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–395. doi:10.1111/joim.1239526212387
  • Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017;37:1551–1557. doi:10.1007/s00296-017-3726-128455559
  • Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.129417936
  • Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977. doi:10.1136/annrheumdis-2016-21071528264816
  • Gillis T, Crane M, Hinkle C, Wei N. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action. Open Access Rheumatol. 2017;9:131–138. doi:10.2147/OARRR28790870
  • Fischer PA, Rapoport RJ. Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies. Open Access Rheumatol. 2018;10:13–19. doi:10.2147/OARRR29445306
  • Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25.18163481
  • Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56:1945–1961. doi:10.1093/rheumatology/kex26028968809
  • Lam NC, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. Am Fam Physician. 2016;94:284–294.27548593
  • Li X, Golubovsky J, Hui-Yuen J, et al. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: a retrospective study of patients. F1000Res. 2015;4:1103. doi:10.12688/f1000research27158444
  • Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23:905–912. doi:10.1177/096120331453256224795067
  • Fiechtner JJ, Montroy T. Six months’ treatment of moderately to severely active systemic lupus erythematosus with repository corticotropin injection: an extension of a single-site, open-label trial. J Immunol Clin Res. 2016;3:1025.
  • Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med. 2016;3:e000180. doi:10.1136/lupus-2016-00018027933199
  • Furie RA, Mitrane M, Zhao E, Becker PM. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study. Lupus Sci Med. 2017;4:e000240. doi:10.1136/lupus-2017-00024029344387
  • Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5:109–129. doi:10.3233/JND-18030829865091
  • Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther. 2012;6:133–139. doi:10.2147/DDDT
  • Levine T, Malone J, Efthimiou P, et al. H.P. Acthar® Gel in dermatomyositis and polymyositis treatment registry: an interim analysis. J Neurol Disord. 2016;4:292. doi:10.4172/2329-6895.1000292
  • Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77:720–727. doi:10.1136/annrheumdis-2017-21204729237618
  • Chopra I, Qin Y, Kranyak J, et al. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records. Ther Adv Respir Dis. 2019;13:1753466619888127. doi:10.1177/175346661988812731722624
  • Nelson WW, Lima AF, Kranyak J, et al. Retrospective medical record review to describe use of repository corticotropin injection among patients with uveitis in the United States. J Ocul Pharmacol Ther. 2019;35(3):182–188. doi:10.1089/jop.2018.009030676837
  • Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. A multicentre study assessing the efficacy and safety of repository corticotropin injection in patients with persistently active rheumatoid arthritis: Poster presented at: The European League Against Rheumatism (EULAR) Annual Congress; June 12–15, 2019; Madrid, Spain.
  • Saygin D, Marder G, Oddis CV, et al. Long term follow-up results of myositis patients treated with H. P. Acthar Gel [abstract]. Arthritis Rheum. 2018;70.
  • Fernandez A. Interim results of an open-label study assessing efficacy and safety of adrenocorticotropic hormone gel for treatment of refractory cutaneous manifestations of dermatomyositis [abstract]. Arthritis Rheum. 2018;70.